Next Article in Journal
Impact of the COVID-19 and Socioeconomic Status on Access to Care for Otorhinolaryngology Patients
Previous Article in Journal
Towards Sustainable Wastewater Treatment: Bioindication as a Technique for Supporting Treatment Efficiency Assessment
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 19
Issue 19
10.3390/ijerph191911871
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Possible Association of Hysterectomy Accompanied with Opportunistic Salpingectomy with Early Menopause: A Retrospective Cohort Study

by
Pei-Chen Chen
1,
Pei-Chen Li
1 and
Dah-Ching Ding
1,2,*
1
Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan
2
Institute of Medical Sciences, Tzu Chi University, Hualien 97004, Taiwan
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2022, 19(19), 11871; https://doi.org/10.3390/ijerph191911871
Submission received: 8 August 2022 / Revised: 16 September 2022 / Accepted: 17 September 2022 / Published: 20 September 2022
Browse Figures
Review Reports Versions Notes

Abstract

:
Opportunistic salpingectomies (OSs) are concurrently performed with hysterectomies to prevent epithelial ovarian cancer. This study aimed to investigate the correlation between OS and early menopause in females who have undergone hysterectomies. This was a retrospective cohort study involving 79 females who had undergone a hysterectomy, with or without an OS, between January 2007 and December 2015. Their ages at surgery, at menopause, and the lengths of time from surgery to menopause were compared. An OS had been performed in 54 and not performed in 25 of the enrolled patients, comprising the OS and non-OS groups. Body mass index was significantly higher in the OS group (OS: 25.27 ± 4.17 vs. non-OS: 22.97 ± 3.27, p = 0.01). Additionally, menopausal sleep problems were more prevalent in the OS group than in the non-OS group (41% vs. 12%, p = 0.01). Notably, the time from surgery to menopause was significantly shorter in the OS group than in the non-OS group (OS: 1.84 ± 1.85 vs. non-OS: 2.93 ± 2.43, p = 0.031). After adjusting the covariates, the OS group was associated with a significantly shorter period between surgery and menopause (p = 0.029). In conclusion, these results showed that a hysterectomy plus an OS might cause earlier menopause than a hysterectomy only. An OS should be preoperatively discussed with patients regarding the possibility of early menopause. The findings of this study require further large-scale investigations to reinforce the results.

Graphical Abstract

1. Introduction

Ovarian cancer (OvCa) is a disease with limited screening strategies for early diagnosis, usually presenting in the advanced stage when first diagnosed, with a high mortality rate, even after treatment [1,2]. Epithelial ovarian cancer (EOC) is the most common form of OvCa with 21,750 new diagnoses and 13,940 related deaths in the United States in 2020 [3]. In Taiwan, 1521 new patients were diagnosed in 2017, with an incidence rate of 9.2 per 100,000 person-years, and was ranked the seventh most common form of female cancer in 2017 [4]. High-grade serous carcinoma (HGSC) is the most prevalent and fatal type, accounting for 60% of EOC diagnoses and 60% of female cancer mortalities [3]. Due to the diagnostic dilemma of EOC, several studies on the effective prevention of EOC have been conducted, highlighting opportunistic salpingectomy (OS) as one of them [5,6,7].
Currently, serous tubal intraepithelial carcinoma (STIC) at the fimbria end of the fallopian tubes is thought to be the precursor of HGSC [3,8,9]. Based on this finding, an OS could prevent HGSC. It has been reported that undergoing an OS is associated with reduced OvCa risk [10,11,12]. In our hospital, since 2007, we have implemented OS in our eligible patients [13]. In 2019, the American College of Obstetrics and Gynecology committee suggested performing an OS at the time of a hysterectomy or pelvic surgery as a benign indication for the primary prevention of OvCa [14]. In addition to the prevention of OvCa, undergoing an OS is not associated with increased perioperative complications, such as increased hospitalization days, blood transfusion requirements, nor postoperative infections, and it is cost-effective [15]. Previous studies have revealed no difference in the long-term ovarian function of concurrent OS during benign gynecologic surgeries, measured through the change in anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and antral follicle count (AFC) postoperatively for three months to five years [16,17]. Owing to the possibility that OS might prevent OvCa, the prevalence of concurrent OS with a hysterectomy has increased ten-fold in the last decade [7].
The ovarian function may be hampered by the cauterization of the mesosalpinx during an OS with damaged blood flow to the ovary. Two techniques of OS are reported, including suture ligation and bipolar electrocautery [18]. However, which technique damages the blood flow to the ovary is unknown. The most-used method in laparoscopic hysterectomy is bipolar electrocautery [13,19].
However, the longest follow-up period after an OS is only 5 years [16]. Consequently, a longer follow-up period to assess ovarian function is required. Notably, the impact of an OS on ovarian function may be to cause early menopause and increase the risk of cardiovascular disease (CVD), metabolic syndrome, osteoporosis, and all-cause mortality [20,21]. The objective of this study was to follow patients who underwent a hysterectomy with or without an OS for 5 to 10 years to analyze the effect of an OS on the onset time of menopause.

2. Materials and Methods

2.1. Data Sources

We used the hospital’s electronic medical history database to retrieve data on patients who had undergone a hysterectomy with or without an OS over a 9-year period (January 2007 to December 2015) and who were followed-up until July 2021.

2.2. Study Design and Participants

This was a retrospective cohort study. We used the health insurance surgical code payment system (hysterectomy: 80416B, 80421B, 80404B, 80403B) in Taiwan to recruit patients who had undergone a hysterectomy in our hospital from 1 January 2007 to 31 December 2015.
The inclusion criteria were females aged 20 to 50 years who had undergone a hysterectomy for benign lesions, including endometriosis, leiomyoma, and prolapse, and who were followed-up until 31 July 2021.
The exclusion criteria were as follows: patients aged >50 years; those with malignant pathology, including uterine, ovarian, or cervical malignancy; partial or complete adnexectomy; loss of baseline characteristic data; and those with menopause before the operation. Menopause before the hysterectomy was defined as amenorrhea for one year according to the admission and nursing note records.
Patients were divided into three subgroups based on age: <40, 40–44, and 45–50 years old. Baseline demographics were collected, including the indication for hysterectomy, surgical approach (open, laparoscopic, or vaginal), and underlying disease such as diabetes mellitus (DM), hypertension, body mass index (BMI), and parity.

2.3. Outcome Measures

Menopause without hysterectomy is defined as amenorrhea for 12 months [22]. However, the diagnostic criteria for menopause in females undergoing a hysterectomy cannot be evaluated based on amenorrhea. Therefore, supportive criteria that can be used to assess menopause in post-hysterectomy patients, including menopausal symptoms, biochemical data, and hormone replacement therapy, were used [23]. In our study, patients with one of the following menopausal criteria were regarded as having menopause: diagnosis of menopause (International Classification of Diseases (ICD) 9/10 627.2/N95.1), those with menopausal symptoms, receiving menopausal hormone therapy (HT), and those with FSH levels of >40 IU/L or low levels of AMH [24,25].

2.4. Statistical Analysis

Student’s t-tests were used to compare continuous variables. Fisher’s exact tests were used to compare the categorical variables. Statistical analyses were conducted using SPSS 25.0 (IBM, Armonk, NY, USA). The linear regression was used to analyze the association between times from surgery to menopause and covariates, presented as β and 95% CIs. We used G*Power 3.1.9.2 to calculate the sample size. To compare the mean difference in time from surgery to menopause between the OS and non-OS groups, we set an effect size of 0.7, α of 0.05, power(1-β) of 0.80, OS to non-OS sample size ratio of 2, and a two-sided test was performed. The estimated sample size was 76 (i.e., 51 and 25 in the OS and non-OS groups, respectively). Statistical significance was set at a p-value of <0.05.

3. Results

3.1. Demography

The search strategy described above retrieved 1084 patients. Overall, 79 patients were included in the study: 45 in the OS group and 25 in the non-OS group (Figure 1). Table 1 shows the demographic characteristics of the patients. The mean age at the time of surgery, parity, hypertension, DM, surgical indications, and HT were not significantly different between the groups. However, BMI was significantly different (OS: 25.27 ± 4.17 vs. non-OS: 22.97 ± 3.27, p = 0.01).

3.2. Menopause Characteristics of the Patients

Among menopausal symptoms, only sleep problems were more prevalent in the OS group than in the non-OS group (41% vs. 12%, respectively, p = 0.01) (Table 2).

3.3. Onset Time of Menopause after Surgery

Table 3 shows the menopausal onset of the patients in both groups. There was no difference in the age at surgery (45 years old), nor at menopause between the two groups. However, the duration from surgery to menopause was significantly shorter in the OS group than in the non-OS group (p = 0.031).

3.4. Subgroup Analysis

A subgroup analysis between menopause and OS in different age groups was performed (Table 4). There were no significant differences in the onset time from surgery to menopause between the OS and non-OS groups based on age.

3.5. Analysis after Adjusting Covariates

A linear regression analysis of time from surgery to menopause considering various covariates was performed (Table 5). The age at surgery, BMI, and parity had no association with time from surgery to menopause. The OS was associated with a significantly shorter period between surgery and menopause (p = 0.029).

4. Discussion

Our study reviewed 79 patients, 54 in the hysterectomy accompanied with OS group and 25 in the hysterectomy-only group. We found that a high BMI and menopausal sleep problem symptoms were more prevalent in the OS group. Additionally, the duration from surgery to menopause was significantly shorter in the OS group than in the non-OS group.

4.1. The Association between Hysterectomy, OS, and Ovarian Function

A hysterectomy can decrease ovarian function by disrupting ovarian blood flow, causing follicular depletion [25,26]. Recently, a concurrent OS with hysterectomy has been shown to significantly decrease the risk of OvCa due to the elimination of the fallopian tubes, the origin of HGSC which contains STIC, TP53, and BRCA1/2 mutations [3,27]. Most studies have supported that an OS does not increase perioperative complications nor decrease long-term ovarian function (with a <5-year follow-up) [10,14,17]. Conversely, our study might reveal a negative association between an OS and early menopause, compared to that of the non-OS group. This difference between ours and previous studies may be due to the longer follow-up times. We enrolled patients over a 9-year period and followed-up on them for more than 5 years. The mechanisms underlying the negative associations between an OS and long-term ovarian function remain unclear and require further long-term follow-up studies [28].
The evaluation of menopause is difficult because of the lack of menstruation after a hysterectomy [23]. Most studies that have evaluated the effect of an OS on ovarian function were based on blood tests measuring AMH, AFC, estradiol, and FSH [29]. However, these biochemical methods for diagnosing menopause have limited value due to the long-term continuous fluctuation of hormones during perimenopause to menopause status, with no definitive biochemical levels for diagnosing menopause [30]. Our study used diagnostic codes, biochemical analysis, HT requirement, and the patients’ self-reported menopausal symptoms to characterize menopause.

4.2. Population Study Regarding OS and Ovarian Functions

Collins et al. conducted a register-based cohort study and recruited 4906 patients between 1988 and 2016 who had undergone a hysterectomy for benign diseases with or without an OS [31]. This was the first study to evaluate long-term ovarian function based on the presence of postmenopausal symptoms for one year postoperatively. The results showed that an OS increased the risk of postmenopausal symptoms (adjusted relative risk 1.33, 95% confidence interval 1.04–1.69) [31]. Chan et al. performed a prospective observational study recruiting 32 patients who had received salpingectomy and also revealed that a salpingectomy impacted ovarian function by observing patients who had undergone salpingectomies for ectopic pregnancies. They found that AFC and 3D Doppler ovarian blood flow were significantly decreased at the salpingectomy site when compared to the corresponding normal side [32].

4.3. Systemic Review Regarding OS and Ovarian Cancer Prevention

The previous systemic review discussed the effect of preventing ovarian cancer after an OS during a hysterectomy [33]. They included 11 studies and found the hazard ratio was 0.65 (95% CI: 0.52–0.81) and the odds ratio was 0.58 (95% CI: 0.36–0.95) for ovarian cancer risk after an OS. Two randomized trials and one observational study showed no influence on ovarian endocrine function after an OS group compared with a non-OS group [33,34,35,36]. However, they concluded that the evidence level was very low for all outcomes. Conversely, our study found that a reduced ovarian function might cause early menopause after an OS group was compared with a non-OS group. Our results need to be confirmed by a large scale well-designed randomized controlled trial.

4.4. The Age Effect on the Association between OS and Ovarian Function

Collins et al. also found females aged 44–49 years had a higher menopausal risk than younger females [31]. The earlier onset of menopause in the OS group may be due to their older age, in which they are closer to a perimenopause or menopause status when compared to younger age groups [31]. More long-term follow-up investigations are required in these younger age groups [31,37]. Our results showed no significant difference among the three age groups at 5- and 10-year follow-ups. Nevertheless, our study revealed a trend of shorter periods from surgery to menopause in the 40–44-year-old group. Further large-scale studies are required to elucidate the underlying mechanisms behind this trend.

4.5. BMI Effect on the Association between OS and Ovarian Functions

A previous retrospective observational study that recruited 1822 patients showed a mean BMI of 24.18 ± 3.78 kg/m2 (overweight) among Chinese women who underwent a salpingectomy for a benign disease [38]. Collins et al. reported no difference in BMI between an OS (26.5 ± 4.5 kg/m2) and non-OS group (26.4 ± 4.7 kg/m2) among Swedish females [31]. However, the relative risk of early menopausal symptoms increased after adjusting for BMI (1.03, 95% CI: 1.01–1.06) [31]. In our study, the BMI was significantly higher in the OS group (25.27 ± 4.17) than in the non-OS group (22.97 ± 3.27). The association between BMI and early menopause in patients of different ethnicities who have undergone an OS requires further exploration.

4.6. The Trends of OS

Since EOC originates from the fallopian tubes, we have been performing an OS concurrently with hysterectomies for benign indications since 2007, with a prevalence of 8% in 2007, which rapidly increased to 80% in 2015 [13].

4.7. Strength and Limitation of the Study

A strength of our study is the long-term 5–10-year follow-up data we have generated, in addition to biochemistry, menopausal symptoms, and HT requirement data. These measurements support a greater clinical association and precise diagnosis of menopause. Additionally, we can continue to follow-up on the younger group to an age which is closer to menopause to improve the limitations of the previous studies. We also collected baseline characteristics to address the confounding factors that can contribute to decreasing ovarian function, such as smoking, BMI, hypertension, and DM [39,40].
A limitation of this study is the small patient cohort. Additionally, the retrospective nature of this study also showed that patient characteristics were as detailed as desired, and the risks of OvCa for each patient were unknown. There is no standard definition of menopause for females undergoing a hysterectomy, meaning different studies have used various biochemical methods and clinical presentations to diagnose menopause. Menopausal symptoms were recalled by the patients, meaning recall bias may have affected this study.

5. Conclusions

In conclusion, our study showed that an OS during a hysterectomy might cause earlier menopause than a hysterectomy only. The consequence of possible earlier menopause might have caused an increase in morbidity and mortality rates, such as CVD, metabolic syndrome, and osteoporosis. Surgeons need to share decision-making with the patient, particularly those with a low risk of OvCa, regarding the benefits and possible impacts of an OS before surgery. These findings require further large-scale studies to reinforce this relationship.

Author Contributions

Conceptualization, P.-C.L. and D.-C.D.; methodology, D.-C.D.; software, D.-C.D.; validation, P.-C.C., P.-C.L. and D.-C.D.; formal analysis, P.-C.C.; investigation, D.-C.D.; resources, D.-C.D.; data curation, P.-C.C.; writing—original draft preparation, P.-C.C.; writing—review and editing, D.-C.D.; visualization, D.-C.D.; supervision, D.-C.D.; project administration, D.-C.D.; funding acquisition, D.-C.D. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Hualien Tzu Chi Hospital and Buddhist Tzu Chi Medical Foundation (TCRD-111-80, TCMF-EP 111-01, TCRD 111-057, and TCMF-ST 111-02).

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethics Committee of the Hualien Tzu Chi Hospital (IRB111-057-B, Date of approval: 12 April 2022).

Informed Consent Statement

Patient consent was waived due to minimal risk.

Data Availability Statement

All data are presented in the manuscript.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, nor interpretation of data; in the writing of the manuscript; nor in the decision to publish the results.

References

  1. Charkhchi, P.; Cybulski, C.; Gronwald, J.; Wong, F.O.; Narod, S.A.; Akbari, M.R. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers 2020, 12, 3730. [Google Scholar] [CrossRef]
  2. Mukherjee, S.; Sundfeldt, K.; Borrebaeck, C.A.K.; Jakobsson, M.E. Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers. Proteomes 2021, 9, 25. [Google Scholar] [CrossRef] [PubMed]
  3. Mei, J.; Tian, H.; Huang, H.-S.; Hsu, C.-F.; Liou, Y.; Wu, N.; Zhang, W.; Chu, T.-Y. Cellular Models of Development of Ovarian High-Grade Serous Carcinoma: A Review of Cell of Origin and Mechanisms of Carcinogenesis. Cell Prolif. 2021, 54, e13029. [Google Scholar] [CrossRef] [PubMed]
  4. Health Promotion Administration Cancer Registry in 2017. Available online: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=4141&pid=12682 (accessed on 20 June 2022).
  5. Pérez-López, F.R.; Ceausu, I.; Depypere, H.; Kehoe, S.; Lambrinoudaki, I.; Mueck, A.; Senturk, L.M.; Simoncini, T.; Stevenson, J.C.; Stute, P.; et al. Interventions to Reduce the Risk of Ovarian and Fallopian Tube Cancer: A European Menopause and Andropause Society Postition Statement. Maturitas 2017, 100, 86–91. [Google Scholar] [CrossRef] [PubMed]
  6. Karia, P.S.; Joshu, C.E.; Visvanathan, K. Uptake and Predictors of Opportunistic Salpingectomy for Ovarian Cancer Risk Reduction in the United States. Cancer Prev. Res. 2021, 14, 1101–1110. [Google Scholar] [CrossRef] [PubMed]
  7. Mandelbaum, R.S.; Adams, C.L.; Yoshihara, K.; Nusbaum, D.J.; Matsuzaki, S.; Matsushima, K.; Klar, M.; Paulson, R.J.; Roman, L.D.; Wright, J.D.; et al. The Rapid Adoption of Opportunistic Salpingectomy at the Time of Hysterectomy for Benign Gynecologic Disease in the United States. Am. J. Obstet. Gynecol. 2020, 223, 721.e1–721.e18. [Google Scholar] [CrossRef]
  8. De Leo, A.; Santini, D.; Ceccarelli, C.; Santandrea, G.; Palicelli, A.; Acquaviva, G.; Chiarucci, F.; Rosini, F.; Ravegnini, G.; Pession, A.; et al. What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. Diagnostics 2021, 11, 697. [Google Scholar] [CrossRef] [PubMed]
  9. Hong, M.-K.; Chu, T.-Y.; Ding, D.-C. The Fallopian Tube Is the Culprit and an Accomplice in Type II Ovarian Cancer: A Review. Tzu Chi Med. J. 2013, 25, 203–205. [Google Scholar] [CrossRef]
  10. Hanley, G.E.; Pearce, C.L.; Talhouk, A.; Kwon, J.S.; Finlayson, S.J.; McAlpine, J.N.; Huntsman, D.G.; Miller, D. Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. JAMA Netw. Open 2022, 5, e2147343. [Google Scholar] [CrossRef] [PubMed]
  11. Falconer, H.; Yin, L.; Grönberg, H.; Altman, D. Ovarian Cancer Risk after Salpingectomy: A Nationwide Population-Based Study. J. Natl. Cancer Inst. 2015, 107, dju410. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Yoon, S.-H.; Kim, S.-N.; Shim, S.-H.; Kang, S.-B.; Lee, S.-J. Bilateral Salpingectomy Can Reduce the Risk of Ovarian Cancer in the General Population: A Meta-Analysis. Eur. J. Cancer 2016, 55, 38–46. [Google Scholar] [CrossRef] [PubMed]
  13. Ding, D.-C.; Huang, C.; Chu, T.-Y.; Wei, Y.-C.; Chen, P.-C.; Hong, M.-K. Trends of Opportunistic Salpingectomy. JSLS 2018, 22, e2018.00004. [Google Scholar] [CrossRef] [PubMed]
  14. ACOG Committee Opinion. No. 774: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention. Obstet. Gynecol. 2019, 133, e279–e284. [Google Scholar] [CrossRef] [PubMed]
  15. Naumann, R.W.; Hughes, B.N.; Brown, J.; Drury, L.K.; Herzog, T.J. The Impact of Opportunistic Salpingectomy on Ovarian Cancer Mortality and Healthcare Costs: A Call for Universal Insurance Coverage. Am. J. Obstet. Gynecol. 2021, 225, 397.e1–397.e6. [Google Scholar] [CrossRef]
  16. Venturella, R.; Lico, D.; Borelli, M.; Imbrogno, M.G.; Cevenini, G.; Zupi, E.; Zullo, F.; Morelli, M. 3 to 5 Years Later: Long-Term Effects of Prophylactic Bilateral Salpingectomy on Ovarian Function. J. Minim. Invasive Gynecol. 2017, 24, 145–150. [Google Scholar] [CrossRef]
  17. Wang, S.; Gu, J. The Effect of Prophylactic Bilateral Salpingectomy on Ovarian Reserve in Patients Who Underwent Laparoscopic Hysterectomy. J. Ovarian Res. 2021, 14, 86. [Google Scholar] [CrossRef]
  18. Nguyen, N.T.; Alabaster, A.; Simmons, S.; Ritterman Weintraub, M.L.; Bethan Powell, C. Opportunistic Salpingectomy Techniques at the Time of Cesarean Delivery: A Retrospective Cohort Study. J. Clin. Gynecol. Obstet. 2019, 8, 70–76. [Google Scholar] [CrossRef]
  19. Giraudet, G.; Rubod, C.; Collinet, P.; Cosson, M. Salpingectomy During Vaginal Hysterectomy: A Surgical Technique to Make It Easier. Obstet. Gynecol. 2018, 132, 271–273. [Google Scholar] [CrossRef]
  20. Kingsberg, S.A.; Larkin, L.C.; Liu, J.H. Clinical Effects of Early or Surgical Menopause. Obstet. Gynecol. 2020, 135, 853–868. [Google Scholar] [CrossRef]
  21. Muka, T.; Oliver-Williams, C.; Kunutsor, S.; Laven, J.S.E.; Fauser, B.C.J.M.; Chowdhury, R.; Kavousi, M.; Franco, O.H. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-Analysis. JAMA Cardiol. 2016, 1, 767–776. [Google Scholar] [CrossRef] [Green Version]
  22. Price, M.A.; Alvarado, B.E.; Rosendaal, N.T.A.; Câmara, S.M.A.; Pirkle, C.M.; Velez, M.P. Early and Surgical Menopause Associated with Higher Framingham Risk Scores for Cardiovascular Disease in the Canadian Longitudinal Study on Aging. Menopause 2021, 28, 484–490. [Google Scholar] [CrossRef]
  23. Peacock, K.; Ketvertis, K.M. Menopause. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2021. [Google Scholar]
  24. Honour, J.W. Biochemistry of the Menopause. Ann. Clin. Biochem. 2018, 55, 18–33. [Google Scholar] [CrossRef] [PubMed]
  25. Moorman, P.G.; Myers, E.R.; Schildkraut, J.M.; Iversen, E.S.; Wang, F.; Warren, N. Effect of Hysterectomy with Ovarian Preservation on Ovarian Function. Obstet. Gynecol. 2011, 118, 1271–1279. [Google Scholar] [CrossRef] [PubMed]
  26. Khadilkar, S. Does Saving Uterus Save Ovaries? J. Obstet. Gynaecol. India 2020, 70, 99–102. [Google Scholar] [CrossRef] [PubMed]
  27. Custódio, N.; Savisaar, R.; Carvalho, C.; Bak-Gordon, P.; Ribeiro, M.I.; Tavares, J.; Nunes, P.B.; Peixoto, A.; Pinto, C.; Escudeiro, C.; et al. Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes. Biomedicines 2022, 10, 199. [Google Scholar] [CrossRef]
  28. Mohamed, A.A.; Yosef, A.H.; James, C.; Al-Hussaini, T.K.; Bedaiwy, M.A.; Amer, S.A.K.S. Ovarian Reserve after Salpingectomy: A Systematic Review and Meta-Analysis. Acta Obstet. Gynecol. Scand. 2017, 96, 795–803. [Google Scholar] [CrossRef]
  29. Harlow, S.D.; Gass, M.; Hall, J.E.; Lobo, R.; Maki, P.; Rebar, R.W.; Sherman, S.; Sluss, P.M.; de Villiers, T.J. STRAW 10 Collaborative Group Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. Menopause 2012, 19, 387–395. [Google Scholar] [CrossRef]
  30. Ambikairajah, A.; Walsh, E.; Cherbuin, N. A Review of Menopause Nomenclature. Reprod. Health 2022, 19, 29. [Google Scholar] [CrossRef]
  31. Collins, E.; Strandell, A.; Granåsen, G.; Idahl, A. Menopausal Symptoms and Surgical Complications after Opportunistic Bilateral Salpingectomy, a Register-Based Cohort Study. Am. J. Obstet. Gynecol. 2019, 220, 85.e1–85.e10. [Google Scholar] [CrossRef]
  32. Chan, C.C.W.; Ng, E.H.Y.; Li, C.F.; Ho, P.C. Impaired Ovarian Blood Flow and Reduced Antral Follicle Count Following Laparoscopic Salpingectomy for Ectopic Pregnancy. Hum. Reprod. 2003, 18, 2175–2180. [Google Scholar] [CrossRef] [Green Version]
  33. Darelius, A.; Lycke, M.; Kindblom, J.M.; Kristjansdottir, B.; Sundfeldt, K.; Strandell, A. Efficacy of Salpingectomy at Hysterectomy to Reduce the Risk of Epithelial Ovarian Cancer: A Systematic Review. BJOG 2017, 124, 880–889. [Google Scholar] [CrossRef] [PubMed]
  34. Morelli, M.; Venturella, R.; Mocciaro, R.; Di Cello, A.; Rania, E.; Lico, D.; D’Alessandro, P.; Zullo, F. Prophylactic Salpingectomy in Premenopausal Low-Risk Women for Ovarian Cancer: Primum Non Nocere. Gynecol. Oncol. 2013, 129, 448–451. [Google Scholar] [CrossRef]
  35. Findley, A.D.; Siedhoff, M.T.; Hobbs, K.A.; Steege, J.F.; Carey, E.T.; McCall, C.A.; Steiner, A.Z. Short-Term Effects of Salpingectomy during Laparoscopic Hysterectomy on Ovarian Reserve: A Pilot Randomized Controlled Trial. Fertil. Steril. 2013, 100, 1704–1708. [Google Scholar] [CrossRef]
  36. Sezik, M.; Ozkaya, O.; Demir, F.; Sezik, H.T.; Kaya, H. Total Salpingectomy during Abdominal Hysterectomy: Effects on Ovarian Reserve and Ovarian Stromal Blood Flow. J. Obstet. Gynaecol. Res. 2007, 33, 863–869. [Google Scholar] [CrossRef] [PubMed]
  37. Buffeteau, A.; Tanguy Le Gac, Y.; Weyl, A.; Chantalat, E.; Guerby, P.; Vidal, F. Rationale for Opportunistic Salpingectomy during Gynecological Surgery for a Benign Condition: A Review of the Available Literature. J. Gynecol. Obstet. Hum. Reprod. 2020, 49, 101829. [Google Scholar] [CrossRef]
  38. Chen, Y.; Du, H.; Bao, L.; Liu, W. Opportunistic Salpingectomy at Benign Gynecological Surgery for Reducing Ovarian Cancer Risk: A 10-Year Single Centre Experience from China and a Literature Review. J. Cancer 2018, 9, 141–147. [Google Scholar] [CrossRef]
  39. Whitcomb, B.W.; Purdue-Smithe, A.C.; Szegda, K.L.; Boutot, M.E.; Hankinson, S.E.; Manson, J.E.; Rosner, B.; Willett, W.C.; Eliassen, A.H.; Bertone-Johnson, E.R. Cigarette Smoking and Risk of Early Natural Menopause. Am. J. Epidemiol. 2018, 187, 696–704. [Google Scholar] [CrossRef]
  40. Silvestris, E.; de Pergola, G.; Rosania, R.; Loverro, G. Obesity as Disruptor of the Female Fertility. Reprod. Biol. Endocrinol. 2018, 16, 22. [Google Scholar] [CrossRef] [PubMed]
Ijerph 19 11871 g001 550
Figure 1. Flow chart of study design. OS: opportunistic salpingectomy; HT: hormone therapy.
Figure 1. Flow chart of study design. OS: opportunistic salpingectomy; HT: hormone therapy.
Ijerph 19 11871 g001
Table
Table 1. Patient demographics between both groups.
Table 1. Patient demographics between both groups.
ItemSurgeryTotalp-Value
OSNon-OS
N 542579
Age at the time of surgery 45.52 ± 3.245.76 ± 3.4745.59 ± 3.260.769
Age group 0.462
<40 y/o4 (7.4%)1 (4%)5 (6.3%)
40–44 y/o9 (16.7%)7 (28%)16 (20.3%)
45–50 y/o41 (75.9%)17 (68%)58 (73.4%)
BMI (kg/m2) 25.27 ± 4.1722.97 ± 3.2724.54 ± 4.030.01 *
BMI group 0.041 *
Underweight1 (1.9%)1 (4%)2 (2.5%)
Normal22 (40.7%)18 (72%)40 (50.6%)
Overweight14 (25.9%)4 (16%)18 (22.8%)
Obese17 (31.5%)2 (8%)19 (24.1%)
Parity 2.26 ± 1.092.24 ± 1.232.25 ± 1.130.947
HTN 3 (5.6%)1 (4%)4 (5.1%)0.623
DM 1 (1.9%)2 (8%)3 (3.8%)0.234
Approach 0.279
Laparoscopic31 (57.4%)12 (48%)43 (54.4%)
Abdominal/open23 (42.6%)12 (48%)35 (44.3%)
Vaginal0 (0%)1 (4%)1 (1.3%)
Indication 0.513
Leiomyoma28 (51.9%)16 (64%)44 (55.7%)
Endometriosis25 (46.3%)9 (36%)34 (43%)
Prolapse1 (1.9%)0 (0%)1 (1.3%)
HT use 39 (72.2%)19 (76%)58 (73.4%)0.724
Data are presented as n or mean ± standard deviation or n (%). * p-value < 0.05 was considered statistically significant after test. OS: opportunistic salpingectomy; HT: hormone therapy; HTN: hypertension; DM: diabetes mellitus; BMI: body mass index; y/o: years old.
Table
Table 2. Menopause characteristics of the patients.
Table 2. Menopause characteristics of the patients.
ItemSurgeryTotalp-Value
OSNon-OS
HT use 39 (72.2%)19 (76%)58 (73.4%)0.724
Menopause symptoms
Hot flush21 (38.9%)12 (57.1%)33 (44%)0.153
Night sweats12 (22.6%)5 (25%)17 (23.3%)0.529
Sleep problems7 (13%)9 (41%)16 (21.1%)0.01 *
Mood changes4 (7.5%)0 (0%)4 (5.6%)0.285
Dryness6 (11.3%)3 (15.8%)9 (12.5%)0.440
Dysuria3 (5.6%)0 (0%)3 (4.1%)0.399
Recurrent UTI0 (0%)0 (0%)0 (0%)1
Sexual dysfunction7 (13%)1 (5.3%)8 (11%)0.328
Data are presented as n or mean ± standard deviation or n (%). * p-value < 0.05 was considered statistically significant after test. UTI: urinary tract infection; OS: opportunistic salpingectomy.
Table
Table 3. Postoperative onset time of menopause.
Table 3. Postoperative onset time of menopause.
ItemSurgeryTotalp-Value
OS (n = 54)Non-OS (n = 25)
N542579
Age at surgery45.52 ± 3.245.76 ± 3.4745.59 ± 3.260.769
Age at menopause47.36 ± 3.948.69 ± 3.9647.78 ± 3.940.165
Surgery to menopause time (years)1.84 ± 1.852.93 ± 2.432.18 ± 2.090.031 *
Data are presented as mean ± standard deviation. * p-value < 0.05 was considered statistically significant after the test. OS: opportunistic salpingectomy.
Table
Table 4. Comparison of the length of time from surgery to menopause between the different surgery groups stratified by age.
Table 4. Comparison of the length of time from surgery to menopause between the different surgery groups stratified by age.
Age GroupItemSurgeryTotalp-Value
OS (n = 54)Non-OS (n = 25)
<40 y/o (n = 5)Surgery to menopause time (years)0.44 ± 0.404.60 ± NA1.27 ± 1.89NA
(n = 4)(n = 1)
40–44 y/o (n = 16)0.80 ± 0.752.86 ± 2.711.60 ± 2.090.094
(n = 9)(n = 7)
45–50 y/o (n = 58)2.21 ± 1.952.86 ± 2.422.40 ± 2.100.286
(n = 41)(n = 17)
Data are presented as mean ± standard deviation. OS: opportunistic salpingectomy.
Table
Table 5. Factors associated with surgery to menopause time.
Table 5. Factors associated with surgery to menopause time.
ItemCrudeAdjusted
β (95% CI)p-Valueβ (95% CI)p-Value
Age at surgery0.02 (−0.12, 0.17)0.7470.02 (−0.13, 0.16)0.814
BMI0.00 (−0.12, 0.12)0.9980.04 (−0.09, 0.16)0.563
Parity0.04 (−0.38, 0.46)0.8440.04 (−0.38, 0.46)0.856
Surgery (OS vs. non-OS)−1.09 (−2.07, −0.1)0.031 *−1.16 (−2.21, −0.12)0.029 *
CI: confidence interval; BMI: body mass index; OS: opportunistic salpingectomy. * p-value < 0.05 was considered statistically significant after test.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Chen, P.-C.; Li, P.-C.; Ding, D.-C. Possible Association of Hysterectomy Accompanied with Opportunistic Salpingectomy with Early Menopause: A Retrospective Cohort Study. Int. J. Environ. Res. Public Health 2022, 19, 11871. https://doi.org/10.3390/ijerph191911871

AMA Style

Chen P-C, Li P-C, Ding D-C. Possible Association of Hysterectomy Accompanied with Opportunistic Salpingectomy with Early Menopause: A Retrospective Cohort Study. International Journal of Environmental Research and Public Health. 2022; 19(19):11871. https://doi.org/10.3390/ijerph191911871

Chicago/Turabian Style

Chen, Pei-Chen, Pei-Chen Li, and Dah-Ching Ding. 2022. "Possible Association of Hysterectomy Accompanied with Opportunistic Salpingectomy with Early Menopause: A Retrospective Cohort Study" International Journal of Environmental Research and Public Health 19, no. 19: 11871. https://doi.org/10.3390/ijerph191911871

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop